Introduction {#s1}
============

Macroautophagy (hereafter autophagy) is a major route for transport of intracellular material into lysosomes or vacuoles in almost all eukaryotes ([@bib42]; [@bib55]). In autophagy, a membrane cisterna called the isolation membrane (or phagophore) is generated, expands, becomes spherical, and closes to form a double membrane vesicle called the autophagosome. During the course of this process, various cytoplasmic components, including proteins, RNA, and organelles, are selectively or non-selectively sequestered into the autophagosome. The autophagosome fuses with the lysosome/vacuole to allow degradation of the contents. An increasing number of studies have suggested that autophagy is involved in the regulation of a wide range of cellular functions, and linked to a variety of human diseases ([@bib1]; [@bib4]; [@bib29]).

Isolation of autophagy-defective mutants of the budding yeast *Saccharomyces cerevisiae* and subsequent analysis of these mutants led to the identification of autophagy-related (*ATG*/Atg) genes/proteins. Among the over 40 Atg proteins that have been identified to date, 19 are directly involved in the biogenesis of the autophagosome induced under starvation ([@bib32]; [@bib42]; [@bib55]). These 'core' Atg proteins constitute six functional units: (i) the Atg1 kinase complex; (ii) Atg9 vesicles; (iii) phosphatidylinositol (PI) 3-kinase (PI3K) complex I; (iv) the Atg2-Atg18 complex; (v) the Atg12 conjugation system; and (vi) the Atg8 conjugation system. In response to starvation, these proteins interact with each other, localize to the site of autophagosome formation in an ordered manner, and organize the pre-autophagosomal structure (PAS) ([@bib32]; [@bib48]; [@bib51]), in which a precursor of the autophagosomal membrane is generated. The molecular basis of PAS organization, including how Atg proteins are recruited to the PAS, is a key question that needs to be addressed to understand the 'nucleation' step in autophagosome formation.

The ubiquitin-like protein Atg12 is covalently attached to a lysine residue in Atg5 via ubiquitin-like conjugation reactions, resulting in the Atg12-Atg5 conjugate ([@bib25]; [@bib26]). Atg12-Atg5 non-covalently interacts with Atg16 (Atg16L in mammals) to form the Atg12-Atg5-Atg16/Atg16L complex (hereafter the Atg16/Atg16L complex) ([@bib22]; [@bib28]; [@bib27]). The Atg16/Atg16L complex is localized to the PAS (or the site of autophagosome formation) and acts as an E3 enzyme to stimulate the conjugation reaction of ubiquitin-like Atg8/LC3-family proteins to the lipid phosphatidylethanolamine (PE) in autophagosome intermediates (i.e., a still-unknown membrane component of the PAS and the isolation membrane) ([@bib50]; [@bib10]; [@bib12]; [@bib8]; [@bib35]). Atg8-PE conjugates promote the expansion of the isolation membrane ([@bib31]; [@bib53]), and also bind to autophagy receptors that recognize specific degradation targets for their selective sequestration into the autophagosome ([@bib9]).

In both yeast and mammals, the recruitment of the Atg16/Atg16L complex to the site of autophagosome formation depends on PI3-phosphate (PI3P) produced by PI3K complex I ([@bib13]; [@bib50]). A recent study in mammalian cells revealed that the PROPPIN family protein WIPI2b binds both Atg16L1 and PI3P to target the Atg16L1 complex to autophagosome formation sites ([@bib5]). In *S. cerevisiae*, Atg21, one of the three WIPI homologs, was shown to mediate this process in a similar manner ([@bib16]). However, knockout of *ATG21* did not completely abrogate the PAS localization of the Atg16 complex or the autophagic activity of cells ([@bib24]; [@bib30]; [@bib47]), suggesting that there is an unknown mechanism which directs the Atg16 complex to the PAS, in addition to the PI3K complex I-PI3P-Atg21 axis.

In this study, we identified the Atg1 kinase complex, which forms a scaffold for PAS organization, as a novel interaction partner of the Atg16 complex, and found that this intercomplex interaction collaborates with the PI3P-dependent mechanism to recruit the Atg16 complex to the PAS. In addition to the stimulation of Atg8 lipidation, the Atg16 complex recruited via this newly discovered mechanism has a specific, non-E3 function: the promotion of PAS scaffold assembly.

Results {#s2}
=======

An Atg12-dependent, PI3P-independent mechanism targets the Atg16 complex to the PAS {#s2-1}
-----------------------------------------------------------------------------------

To clarify the mechanism that directs the Atg16 complex to the PAS, we carefully analyzed the PAS localization of this complex in cells lacking different Atg proteins ([Figure 1](#fig1){ref-type="fig"}). In this analysis, the Atg16 complex was visualized by Atg5-GFP, and the PAS was labeled with the scaffold protein Atg17 fused with mCherry ([@bib50]). In the currently accepted model, Atg5 and Atg16 cooperate to target the complex to the PAS, whereas Atg12 is dispensable for this process ([@bib50]). It is also believed that PI3P produced by PI3K complex I, which contains Atg14 as a specific subunit, is essential for the localization of the Atg16 complex to the PAS. This PI3P-dependency could, at least in part, be explained by the role of the PI3P-binding protein Atg21 that interacts with Atg16 to recruit the Atg16 complex to the PAS ([@bib30]; [@bib16]). In agreement with this model, the PAS localization of Atg5 was lost by deletion of *ATG16* ([Figure 1](#fig1){ref-type="fig"}). It was also confirmed that Atg5 localized to the PAS less efficiently in the absence of Atg21. Deletion of *ATG14* decreased the PAS localization of Atg5; however, Atg5 still significantly localized to the PAS even without Atg14, to an extent similar to that observed in cells lacking Atg21. In addition, we noticed that the frequency of Atg5 localization to the PAS was decreased in the absence of Atg12, although it abnormally accumulated at the PAS. We found that PAS localization of Atg5 was totally abolished in cells lacking both Atg14 and Atg12 ([Figure 1](#fig1){ref-type="fig"}). Disruption of *ATG12* also abrogated the residual PAS localization of Atg5 in *ATG21* knockout cells. These results suggest that in addition to the previously described PI3P-dependent pathway, there exists an uncharacterized, PI3P-independent mechanism that targets the Atg16 complex to the PAS, which likely involves Atg12.

![Atg12- and PI3P-dependent mechanisms cooperatively act to recruit the Atg16 complex to the PAS.\
Cells expressing Atg5-GFP and Atg17-mCherry were treated with rapamycin for 90 min, and analyzed by fluorescence microscopy. DIC, Differential interference contrast microscopy. Bars, 5 μm. The ratios of Atg17-mCherry puncta positive for Atg5-GFP to total Atg17-mCherry puncta were calculated, and the mean values are shown with standard deviations (n = 3). \*\*p\<0.01; \*\*\*p\<0.001 (unpaired two-tailed Student's *t*-test).](elife-43088-fig1){#fig1}

The Atg16 complex interacts with the Atg1 complex under autophagy-inducing conditions {#s2-2}
-------------------------------------------------------------------------------------

We proceeded to investigate an Atg12-dependent mechanism for PAS-targeting of the Atg16 complex. Yeast cells expressing FLAG-tagged Atg5 (Atg5-FLAG) were treated with rapamycin, which inhibits Tor kinase complex 1 and thereby induces various starvation responses including autophagy even in the presence of nutrients ([@bib41]), followed by immunoprecipitation using anti-FLAG antibody. Mass spectrometry of the immunoprecipitates identified a number of proteins as possible interaction partners of the Atg16 complex, and included most components of the Atg1 complex ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}). The Atg1 complex is composed of the protein kinase Atg1 and the regulatory and scaffold proteins Atg13, Atg17, Atg29, and Atg31, and triggers autophagosome formation in response to nutrient starvation ([@bib7]; [@bib18]). Atg1, Atg17, and Atg29 could also be detected in Atg5-FLAG immunoprecipitates by immunoblotting ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). When *ATG12* or *ATG16* was deleted, coimmunoprecipitation of Atg17 with Atg5-FLAG was largely decreased ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). We also showed that Atg17 was not precipitated with Atg5-FLAG in the absence of Atg10, which is essential for Atg12 conjugation to Atg5 ([@bib25]) ([Figure 2A](#fig2){ref-type="fig"}). Immunoprecipitation of FLAG-tagged Atg16 also precipitated Atg17; however, this was lost by knockout of *ATG5* or *ATG12* ([Figure 2B](#fig2){ref-type="fig"}). Thus, the formation of the Atg16 complex is required for its interaction with the Atg1 complex. We also examined this interaction in cells lacking any of the components of the Atg1 kinase complex. In this analysis, coprecipitation of Atg1 with Atg5-FLAG was also examined to evaluate the effect of *ATG17* knockout on the association between the two complexes. The results clearly showed that all the components of the Atg1 complex are important for its interaction with the Atg16 complex ([Figure 2C](#fig2){ref-type="fig"}). In addition, the F430A mutation in Atg13, which impairs the formation of the Atg1 complex ([@bib54]), reduced Atg17 precipitation with the Atg16 complex ([Figure 2D](#fig2){ref-type="fig"}). These results suggest that the formation of the Atg1 complex is a prerequisite for its association with the Atg16 complex. In contrast, *ATG14* deletion did not affect Atg17 precipitation with Atg5-FLAG ([Figure 2E](#fig2){ref-type="fig"}), consistent with the idea that this novel intercomplex interaction is involved in the PI3P-independent PAS targeting of the Atg16 complex.

![The Atg16 complex interacts with the Atg1 complex.\
(**A--C, E**) Yeast cells expressing Atg5-FLAG (**A, C--E**) or Atg16-FLAG (**B**) from each chromosomal locus were treated with rapamycin for 2 hr, and subjected to immunoprecipitation using anti-FLAG antibody. The immunoprecipitates were analyzed by immunoblotting using antibodies against FLAG (**A, B**), Atg12 (**C, E**), Atg17 (**A--C, E**), and Atg1 (**C**). (**D**) *atg13*Δ cells expressing wild-type Atg13, the F375A mutant, or the F430A mutant from centromeric plasmids were treated with rapamycin for 2 hr, subjected to immunoprecipitation using anti-FLAG antibody, and the immunoprecipitates were analyzed by immunoblotting using antibodies against Atg12, Atg13 and Atg17. (**F**) Yeast cells were treated with or without rapamycin for 2 hr, and coimmunoprecipitation of Atg17 with Atg5-FLAG was examined as described in [Figure 2C](#fig2){ref-type="fig"}. (**G**) Coimmunoprecipitation of Atg17 with Atg5-FLAG was analyzed in cells expressing wild-type Atg1 or the D211A mutant from the original chromosomal locus as described in [Figure 2C](#fig2){ref-type="fig"}.](elife-43088-fig2){#fig2}

We found that the Atg16 complex interacts with the Atg1 complex depending on cell treatment with rapamycin ([Figure 2F](#fig2){ref-type="fig"}). Consistent with this result, the interaction was not considerably decreased by the absence of Atg11, which binds to the Atg1 complex but is dispensable for starvation-induced autophagy ([@bib18]; [@bib20]). Upon nutrient starvation, Atg1, Atg13, and the Atg17-Atg29-Atg31 complex form the Atg1 complex, and multiple copies of the complex further associate with each other, leading to activation of Atg1 kinase via intermolecular autophosphorylation ([@bib54]; [@bib57]; [@bib56]). This assemblage of the Atg1 complexes serves as a scaffold to recruit downstream Atg proteins for PAS organization. The interaction between the Atg16 complex and the Atg1 complex was lost in the F375A mutant of Atg13 ([Figure 2D](#fig2){ref-type="fig"}), which can form the Atg1 complex, but is defective in its higher order assembly ([@bib54]). By contrast, the D211A mutation in Atg1, which abolishes its kinase activity ([@bib23]), did not affect the interaction between the Atg16 and Atg1 complexes ([Figure 2G](#fig2){ref-type="fig"}). These results suggest that the Atg16 complex associates with the Atg1 complex following its supramolecular assembly in a manner independent of Atg1 kinase activity.

We also examined which subunits mediate the interaction between the Atg16 and Atg1 complexes. Yeast two-hybrid assay suggested that Atg12 could bind Atg17 and Atg31 ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). In this assay, the Atg12-Atg17 interaction was still observed in *atg13*Δ *atg31*Δ cells ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}), in which Atg17 should not interact with the remaining subunits Atg1 and Atg29. By contrast, the Atg12-Atg31 interaction was abolished by *ATG17* knockout, suggesting that Atg12 interacted with Atg31 via Atg17 ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). In addition, immunoprecipitation of Atg12 C-terminally fused with GFP, which is not associated with Atg5 and Atg16, coprecipitated Atg17 in cells lacking the other four subunits of the Atg1 complex, when both of Atg12-GFP and Atg17 were overexpressed. These results suggest that the interaction between Atg17 and Atg12 mediates the association of the two complexes.

The Atg16 complex interacts with the Atg1 complex to localize to the PAS {#s2-3}
------------------------------------------------------------------------

Next, we examined the significance of the interaction between the Atg16 and Atg1 complexes in autophagosome formation. Atg12 is a ubiquitin-like protein with an approximately 100 amino acid-long extension at the N terminus ([@bib49]). A previous study reported that while the ubiquitin-like domain of Atg12 was essential for autophagy, deletion of the N-terminal region caused a partial defect ([@bib11]). The N-terminal region of Atg12 was not required for Atg12 conjugation to Atg5, the E3 activity of the conjugate, or the interaction of the conjugate with Atg16 ([@bib11]) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Thus, the role for the Atg12 N-terminal region remained unknown. We found that the Atg1 complex was hardly coimmunoprecipitated with the Atg16 complex that contained Atg12 lacking the N-terminal 56 residues (Atg12^ΔN56^) ([Figure 3A](#fig3){ref-type="fig"}), suggesting that the Atg12 N-terminal region is involved in the interaction of the Atg16 complex with the Atg1 complex. The results obtained by fluorescence microscopy ([Figure 1](#fig1){ref-type="fig"}) suggested that this interaction cooperates with the PI3P-dependent pathway in the recruitment of the Atg16 complex to the PAS. Therefore, we examined the PAS localization of the complex containing Atg12^ΔN56^ in the absence of Atg21. While expression of wild-type Atg12 rescued a defect in the PAS localization of Atg5-GFP in *atg21*Δ *atg12*Δ cells, expression of the Atg12^ΔN56^ mutant did not ([Figure 3B](#fig3){ref-type="fig"}). We also performed an alkaline phosphatase (ALP) assay to assess autophagic activity in the mutant cells. In this assay, a mutant form of the vacuolar phosphatase Pho8 (Pho8Δ60) is expressed in an unprocessed, inactive form in the cytoplasm. This mutant phosphatase is delivered into the vacuole through autophagy. Once inside the vacuole, it is processed into an active form, and its activity can be quantified biochemically ([@bib38]). Consistent with previous results ([@bib11]; [@bib24]; [@bib47]), *atg12^ΔN56^* cells (*atg12*Δ cells carrying the *atg12^ΔN56^* plasmid) and *atg21*Δ cells (*atg21*Δ *atg12*Δ cells carrying the *ATG12*^WT^ plasmid) were only partially defective in autophagy ([Figure 3C](#fig3){ref-type="fig"}). When these mutations were combined (*atg21*Δ *atg12*Δ cells carrying the *atg12^ΔN56^* plasmid), the cells showed almost no autophagic activity. These results suggest that the interaction of the Atg16 complex with the Atg1 complex indeed acts to target the Atg16 complex to the PAS, and that defects caused by the absence of this interaction can be partly compensated by the PI3P-dependent mechanism. If both of these mechanisms are simultaneously compromized, cells totally lose their ability to form the autophagosome.

![The interaction of the Atg16 complex with the Atg1 complex is involved in the PAS targeting of the Atg16 complex.\
(**A**) *atg12*Δ cells expressing wild-type Atg12 or Atg12^ΔN56^ from centromeric plasmids were treated with rapamycin for 2 hr, and examined for coimmunoprecipitation of Atg17 with Atg5-FLAG as described in [Figure 2C](#fig2){ref-type="fig"}. The upper and middle panels were immunoblots obtained using antibodies against Atg5 and FLAG, respectively. Asterisk, non-specific bands. (**B**) Yeast cells were treated with rapamycin for 2 hr, and the PAS localization of Atg5-GFP was assessed by fluorescence microscopy as described in [Figure 1](#fig1){ref-type="fig"}. \*\*p\<0.01; \*\*\*p\<0.001 (unpaired two-tailed Student's *t*-test). (**C**) *atg12*Δ and *atg12*Δ *atg21*Δ cells expressing wild-type Atg12 or Atg12^ΔN56^ from centromeric plasmids were grown in nutrient-rich medium (open bars) and then starved in SD-N medium for 4 hr (closed bars), and their autophagic activities were evaluated by ALP assay. The mean values are shown with standard deviations (n = 3). \*p\<0.05; \*\*p\<0.01 (unpaired two-tailed Student's *t*-test).](elife-43088-fig3){#fig3}

The Atg16 complex recruited via the Atg12-dependent pathway plays two different roles in PAS organization {#s2-4}
---------------------------------------------------------------------------------------------------------

Previous studies showed that PI3P-dependent PAS recruitment of the Atg16 complex is important for the production of Atg8-PE ([@bib24]; [@bib47]). We asked whether the Atg12-dependent mechanism also contributes to this process. Atg8-PE production is stimulated upon nitrogen starvation ([Figure 4A](#fig4){ref-type="fig"}, *atg12*Δ/p*ATG12*^WT^). As reported previously ([@bib24]; [@bib47]), *ATG21* knockout significantly reduced the level of Atg8-PE, which still gradually increased during nitrogen starvation (*atg21*Δ *atg12*Δ/p*ATG12*^WT^). We found that deletion of the N-terminal region of Atg12 also partially decreased Atg8-PE formation (*atg12*Δ/p*atg12*^Δ^*^N56^*). In addition, starvation-induced Atg8-PE formation was totally abolished in cells lacking both Atg21 and the N-terminal region of Atg12 (*atg21*Δ *atg12*Δ/p*atg12*^Δ^*^N56^*). Of note, the residual amount of Atg8-PE in these mutant cells should represent the conjugates that were produced in the vacuolar membrane depending on the Atg16 complex, which is dispersed throughout the cytoplasm, independent of autophagy ([@bib33]). These results demonstrated that the Atg16 complex recruited by the Atg12-dependent mechanism acts as an E3 enzyme and promotes Atg8 lipidation, as was observed with the PI3P-dependent mechanism.

![The Atg16 complex recruited via the association with the Atg1 complex facilitates Atg8 lipidation and PAS scaffold assembly.\
(**A**) Yeast cells were incubated in nitrogen starvation medium and examined for the production of Atg8-PE by urea-SDS-PAGE and immunoblotting using anti-Atg8 antibodies (see Materials and methods). The ratio of Atg8-PE to total Atg8 was calculated, and the mean values are shown with standard deviations (n = 3). \*p\<0.05; \*\*p\<0.01 (unpaired two-tailed Student's *t*-test). Pgk1 serves as a loading control. (**B and C**) Yeast cells expressing Atg17-GFP were treated with rapamycin for 90 min (**B**) or 2 hr (**C**), and observed under a fluorescence microscope. The proportion of cells containing Atg17-GFP puncta to total cells was calculated, and the mean values are shown with standard deviations (n = 3). \*\*p\<0.01 (unpaired two-tailed Student's *t*-test).](elife-43088-fig4){#fig4}

We noticed that Atg17-GFP puncta, which represent PAS scaffold assembly ([@bib54]), were decreased by knockout of *ATG12*, which disrupts the Atg12-dependent mechanism, whereas the puncta were increased by knockout of *ATG14* or *ATG21*, which impairs the PI3P-dependent mechanism ([Figure 1](#fig1){ref-type="fig"}). We confirmed this finding using *atg11*Δ cells, in which the starvation-induced assembly of the PAS scaffold can be assessed separately from a similar process that occurs under nutrient-replete conditions for the cytoplasm-to-vacuole targeting (Cvt) pathway ([@bib3]; [@bib19]). The results demonstrated that the formation of Atg17-GFP puncta upon rapamycin treatment was defective in the absence of Atg12, Atg5, or Atg16 ([Figure 4B](#fig4){ref-type="fig"}). More importantly, Atg17-GFP puncta were also decreased by deletion of the N-terminal region of Atg12 ([Figure 4C](#fig4){ref-type="fig"}). These results suggest that the Atg16 complex recruited via the Atg12-dependent mechanism (i.e., the interaction with the Atg1 complex) facilitates starvation-induced PAS scaffold assembly.

Discussion {#s3}
==========

Previous studies established a model for PAS targeting of the Atg16 complex: Atg16 interacts with Atg21, which binds PI3P produced by PI3K complex I at the PAS ([@bib16]; [@bib30]; [@bib24]; [@bib47]) ([Figure 5](#fig5){ref-type="fig"}, PI3P-dependent targeting). This model nicely explained the PI3P-dependency of the process. However, disruption of *ATG21* or *ATG14* did not totally abolish PAS localization of the Atg16 complex, suggesting the existence of another pathway that targets this complex to the PAS in a PI3P-independent manner. In this study, we discovered that the Atg16 complex also interacts with the Atg1 complex via the N-terminal region of Atg12 to localize to the PAS ([Figure 5](#fig5){ref-type="fig"}, Atg12-dependent targeting). Thus, the Atg16 complex is recruited to the PAS through two different pathways. Although disrupting either of the pathways caused partial defects, in the absence of both of these pathways, the Atg16 complex hardly localized to the PAS, and autophagy was completely blocked. These results suggested that these pathways function in a partially redundant manner. Consistent with this idea, we showed that these pathways cooperatively act to stimulate Atg8-PE formation in response to starvation ([Figure 4A](#fig4){ref-type="fig"}). However, the Atg1 complex serves as a scaffold to initiate PAS organization, whereas Atg21 is recruited at a later step, following the production of PI3P by PI3K complex I ([Figure 5](#fig5){ref-type="fig"}), suggesting that there is a functional difference between these pathways. Indeed, we found that the Atg12-dependent pathway, but not the PI3P-dependent pathway, is involved in PAS scaffold assembly. Thus, the Atg16 complex recruited by the Atg12-dependent pathway has a specific, non-E3 role in the initiation of PAS organization. Given the complementary relationship with the PI3P-dependent pathway, it is likely that the Atg16 complex recruited through the association of the Atg1 complex also contributes to Atg8 lipidation at later stages ([Figure 5](#fig5){ref-type="fig"}, dashed arrow).

![Model for the PAS recruitment of the Atg16 complex.\
The Atg16 complex is recruited to the PAS through two different pathways (Atg12-dependent targeting and PI3P-dependent targeting). Upon autophagy induction (starvation or TORC1 inactivation), the Atg1 complex is assembled, and multiple copies of Atg1 complexes further form a higher order assembly. During the process, the Atg16 complex associates with Atg1 complexes via the N-terminal region of Atg12, promoting PAS scaffold assembly. The Atg16 complex recruited at this stage also facilitates lipidation of Atg8 at a later stage in PAS organization (dashed arrow). As reported previously, following the recruitment of PI3K complex I and the production of PI3P by this complex, the Atg16 complex localizes to the PAS via the interaction with the PI3P-binding protein Atg21 to stimulate Atg8 lipidation.](elife-43088-fig5){#fig5}

The interaction between the Atg16 complex and the Atg1 complex required both of the complexes to be intact. In addition, higher order assembly of Atg1 complexes was a prerequisite for the interaction ([Figure 2D](#fig2){ref-type="fig"}). We speculate that the Atg16 complex, in which Atg12-Atg5-Atg16 is dimerized by the homodimerization of Atg16 ([@bib6]), simultaneously binds to two copies of the Atg1 complexes via the N-terminal regions of Atg12 ([Figure 5](#fig5){ref-type="fig"}). This mode of interaction can crosslink the Atg1 complexes, resulting in the facilitation of supramolecular assembly of Atg1 complexes to form the PAS scaffold.

In this study, we showed that the association between the Atg16 and Atg1 complexes requires the N-terminal region of Atg12. Although there is no sequence similarity between the N-terminal regions of yeast and mammalian Atg12, a recent study revealed that the Atg16L complex also associates with the ULK1 complex (corresponding to the Atg1 complex) in mammalian cells ([@bib37]). This intercomplex association was mediated by the interaction between Atg16L and FIP200, which is a mammalian counterpart of yeast Atg17, and important for the localization of the Atg16L complex to the isolation membrane. Thus, although the underlying mechanisms are different, the recruitment of the Atg16/Atg16L complex to autophagosome intermediates through association with the Atg1/ULK1 complex is a common process during autophagosome formation in yeast and mammals. It is still unclear how this process cooperates with the PI3P (WIPI2)-dependent mechanism in mammalian cells. The Atg16L complex may also facilitate supramolecular assembly of ULK complexes in the initiation of autophagosome formation.

Materials and methods {#s4}
=====================

Yeast strains and media {#s4-1}
-----------------------

*S. cerevisiae* strains used in this study are listed in [Table 1](#table1){ref-type="table"}. Gene knockout and tagging were performed as described previously ([@bib14]). Yeast cells were grown at 30°C in YPD medium (1% yeast extract, 2% peptone, and 2% glucose) for immunoprecipitation analysis or in SD+CA+ATU medium \[0.17% yeast nitrogen base without amino acids and ammonium sulfate (YNB w/o aa and as), 0.5% ammonium sulfate, 0.5% casamino acids, and 2% glucose supplemented with 0.002% adenine sulfate, 0.002% tryptophan, and 0.002% uracil\] for fluorescence microscopy. Cells carrying pRS316-derived plasmids expressing Atg12, Atg13, and their mutants were cultured in SD+CA+ATU without uracil. To induce autophagy, cells were treated with 0.2 μg/mL rapamycin or incubated in SD-N medium (0.17% YNB w/o aa and as and 2% glucose).
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###### Yeast strains used in this study.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Name**   Genotype                                                                                                                                                            Figures                   Reference
  ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ------------
  W303-1a    *MATa ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100*                                                                                                          \-                        ([@bib52])

  ScKH146    W303-1A, *ade2*::*ADE2 ATG5-EGFP-kanMX6*\                                                                                                                           1A                        This study
             *ATG17-2×mCherry-hphNT1*                                                                                                                                                                      

  ScKH153    ScKH146 *atg16*Δ::*natNT2*                                                                                                                                          1A                        This study

  ScKH182    ScKH146 *atg21*Δ::*zeoNT3*                                                                                                                                          1A                        This study

  ScKH151    ScKH146 *atg14*Δ::*natNT2*                                                                                                                                          1A                        This study

  ScKH149    ScKH146 *atg12*Δ::*natNT2*                                                                                                                                          1A                        This study

  ScKH162    ScKH146 *atg14*Δ::*natNT2 atg12*Δ::*zeoNT3*                                                                                                                         1A                        This study

  ScTK623    ScKH146 *atg21*Δ::*natNT2 atg12*Δ::*zeoNT3*                                                                                                                         1A                        This study

  BJ2168     *MATa leu2 trp1 ura3-52 prb1-1122 pep4-3 prc1-407 gal2*                                                                                                             2A-C, 2E, 2F, 2-S1A,\     ([@bib15])
                                                                                                                                                                                 2-S1C                     

  MAN169     BJ2168 *ATG5-TEV-3×FLAG-kanMX4*                                                                                                                                     2A, 2C, 2E, 2F, 2-S1A,\   This study
                                                                                                                                                                                 2-S1C                     

  ScKH10     MAN169 *atg16*Δ::*natNT2*                                                                                                                                           2A, 2E,\                  This study
                                                                                                                                                                                 2-S1A                     

  ScKH32     MAN169 *atg12*Δ::*natNT2*                                                                                                                                           2A, 3A                    This study

  ScKH96     MAN169 *atg10*Δ::*natNT2*                                                                                                                                           2A                        This study

  ScKH90     BJ2168 *ATG16-TEV-3×FLAG-kanMX4*                                                                                                                                    2B                        This study

  ScKH92     ScKH90 *atg5*Δ::*natNT2*                                                                                                                                            2B                        This study

  ScKH93     ScKH90 *atg12*Δ::*natNT2*                                                                                                                                           2B                        This study

  ScKH141    MAN169 *atg1*Δ::*natNT2*                                                                                                                                            2C                        This study

  ScKH99     MAN169 *atg13*Δ::*natNT2*                                                                                                                                           2C, 2D                    This study

  ScKH216    MAN169 *atg17*Δ::*natNT2*                                                                                                                                           2C                        This study

  ScKH101    MAN169 *atg29*Δ::*natNT2*                                                                                                                                           2C                        This study

  ScKH143    MAN169 *atg31*Δ::*natNT2*                                                                                                                                           2C                        This study

  ScKH98     MAN169 *atg14*Δ::*natNT2*                                                                                                                                           2E                        This study

  ScKH97     MAN169 *atg11*Δ::*natNT2*                                                                                                                                           2F                        This study

  ScYH3184   BJ2168 *leu2*::*LEU2*                                                                                                                                               2G                        This study

  ScKH66     ScHY3184 *ATG5-TEV-3×FLAG-kanMX4*                                                                                                                                   2G                        This study

  ScKH68     ScHY3184 *atg1^D211A^*-*hphNT1 ATG5-TEV-3×FLAG-kanMX4*                                                                                                              2G                        This study

  AH109      *MATa trp1-901 leu2-3*, *112 ura3-52 his3-200 gal4*Δ *gal80*Δ*LYS2*::*GAL1~UAS~-GAL1~TATA~-HIS3 MEL1 GAL2~UAS~-GAL2~TATA~-ADE2 URA3*::*MEL1~UAS~-MEL1~TATA~-lacZ*   2-S2A                     Clontech

  ScTK967    AH109 *atg13*Δ::*natNT2 atg31*Δ::*hphNT1*                                                                                                                           2-S2B                     This study

  ScTK968    AH109 *atg17*Δ::*natNT2*                                                                                                                                            2-S2C                     This study

  ScTK877    BJ2168 *atg11*Δ::*LEU2 atg29*Δ::*zeoNT3 atg31*Δ::*hphNT1 atg1*Δ::*natNT2 atg13*Δ::*Klura3 P~ADH1~-ATG17-CgTRP1*                                                     2-S2D                     This study

  ScTK958    ScTK877 *KlURA3-P~ADH1~-ATG12-EGFP-kanMX4*                                                                                                                          2-S2D                     This study

  ScTK649    ScTK623 *his3-11*::pRS303                                                                                                                                           3B                        This study

  ScTK650    ScTK623 *his3-11*::pRS303*-ATG12*                                                                                                                                   3B                        This study

  ScTK651    ScTK623 *his3-11*::pRS303*-atg12*^Δ^*^N56^*                                                                                                                         3B                        This study

  BY4741     *MATa his3*Δ*1 leu2*Δ*0 met15*Δ*0 ura3*Δ*0*                                                                                                                         \-                        ([@bib2])

  ScTK557    BY4741 *pho8*Δ::*kanMX4- P~GPD~-pho8*Δ*60 atg12*Δ::*natNT2*                                                                                                         3C, 4A                    This study

  ScTK559    BY4741 *pho8*Δ::*kanMX4- P~GPD~-pho8*Δ*60 atg21*Δ::*zeoNT3 atg12*Δ::*natNT2*                                                                                        3C, 4A                    This study

  ScKH119    W303-1A, *ade2*Δ::*ADE2 ATG17-EGFP-kanMX4 atg11*Δ::*zeoNT3*                                                                                                         4B                        This study

  ScKH121    ScKH119 *atg5*Δ::*natNT2*                                                                                                                                           4B                        This study

  ScKH123    ScKH119 *atg12*Δ::*natNT2*                                                                                                                                          4B                        This study

  ScKH125    ScKH119 *atg16*Δ::*natNT2*                                                                                                                                          4B                        This study

  ScTK657    YKH123 *his3-11*::pRS303                                                                                                                                            4C                        This study

  ScTK658    YKH123 *his3-11*::pRS303*-ATG12*                                                                                                                                    4C                        This study

  ScTK659    YKH123 *his3-11*::pRS303*-atg12*^Δ^*^N56^*                                                                                                                          4C                        This study
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plasmids {#s4-2}
--------

pRS316-based centromeric plasmids for expression of Atg13 mutants were described previously ([@bib54]). Plasmids for Atg12 expression were constructed as follows. pRS424-*ATG12* ([@bib11]) was digested by *Sac*I and *Xho*I, and a DNA fragment encompassing the *ATG12* gene was ligated with the pRS316 vector ([@bib46]) cut with the same enzymes, resulting in pRS316-*ATG12*. The nucleotide sequence encoding Ser2 to Gln56 of Atg12 was removed from this plasmid using the QuikChange site-directed mutagenesis kit (Agilent Technologies) to obtain the plasmid expressing Atg12^ΔN56^ (pRS316-*atg12*^Δ^*^N56^*). DNA fragments excised from these plasmids were ligated with the pRS303 vector ([@bib46]) in the same manner to construct pRS303-*ATG12* and pRS303-*atg12*^Δ^*^N56^*. These plasmids were digested by *Nhe*I prior to their introduction into yeast cells for integration at the *HIS3* locus. pGAD-*ATG1*, pGAD-*ATG13*, pGAD-*ATG17*, pGAD-*ATG19*, pGBD-*ATG8*, and pGBD-*ATG12* for yeast two-hybrid assay were described previously ([@bib17]; [@bib18]; [@bib27]; [@bib34]; [@bib39]). To construct pGAD-*ATG29* and pGAD-*ATG31*, the open reading frames of *ATG29* and *ATG31* were cloned into the *Bam*HI and *Pst*I sites on pGAD-C1 using the Gibson assembly kit (New England Biolabs).

Fluorescence microscopy {#s4-3}
-----------------------

Fluorescence microscopy was performed using an inverted fluorescence microscope (IX83; Olympus) equipped with an electron-multiplying CCD camera (ImagEM C9100-13; Hamamatsu Photonics), and a 150× objective lens (UAPON 150XOTIRF, NA/1.45; Olympus). GFP and mCherry were excited using a 488 nm blue laser (50 mW; Coherent) and a 588 nm yellow laser (50 mW; Coherent), respectively. Fluorescence was filtered with a dichroic mirror reflecting 405 nm, 488 nm, and 588 nm wavelengths (Olympus), separated into two channels using the DV2 multichannel imaging system (Photometrics) equipped with a Di02-R594-25×36 dichroic mirror (Semrock), and further filtered with the TRF59001-EM ET bandpass filter (Chroma) for the GFP channel and the FF01-624/40-25 bandpass filter (Semrock) for the mCherry channel. Images were acquired using MetaMorph software (Molecular Devices) and processed using Fiji (ImageJ) ([@bib44]; [@bib45]).

Immunoprecipitation {#s4-4}
-------------------

Cells expressing FLAG-tagged proteins were grown to mid-log phase and converted to spheroplasts by incubating them in 0.5× YPD or 0.5× SD+CA+ATU medium containing 1 M sorbitol and 0.1 mg/mL zymolyase 100T (Nacalai tesque) at 30°C for 45 min. These cells were then washed with 20 mM HEPES-KOH (pH7.2) containing 1.2 M sorbitol, and incubated in 0.5× YPD or 0.5× SD+CA+ATU medium containing 1 M sorbitol and 0.2 μg/mL rapamycin at 30°C for 2 hr. The cells were pelleted and solubilized in IP buffer \[50 mM Tris-HCl (pH8.0), 150 mM NaCl, 10% glycerol, 5 mM EDTA, 5 mM EGTA, and 50 mM NaF\] containing 2 mM phenylmethylsulfonyl fluoride (PMSF), 2× cOmplete Protease Inhibitor Cocktail (Roche), and 1% n-dodecyl-β-maltoside (DDM). After removal of cell debris by centrifugation at 15,000 *g* for 20 min, the resulting supernatants (input) were incubated with NHS FG-beads (Tamagawa Seiki) conjugated with anti-FLAG M2 antibody (F1804; Sigma-Aldrich) or GFP-nanobody (GFP-binding protein) ([@bib21]) and rotated at 4°C for 2 hr. The beads were washed three times with IP buffer containing 0.1% DDM, and bound proteins were eluted with SDS sample buffer \[50 mM Tris-HCl (pH7.5), 2% SDS, 8% glycerol, and a trace amount of bromophenol blue\] at 65°C for 10 min. Dithiothreitol was added to these samples to a final concentration of 100 mM, and they were incubated at 65°C for 10 min. The samples were analyzed by immunoblotting using antibodies against FLAG (F1804; Sigma), Atg12, Atg5, Atg1, Atg13, Atg17, Atg29, and Atg31 ([@bib22]; [@bib23]; [@bib18]; [@bib19]).

Analysis of Atg8 lipidation {#s4-5}
---------------------------

Yeast cells were grown to mid-log phase, treated with 1 mM PMSF for 10 min, and subjected to starvation in SD-N medium containing 1 mM PMSF. Samples for immunoblotting analysis were prepared as described previously ([@bib21]), and subjected to urea-SDS-PAGE ([@bib36]) to separate lipidated Atg8 (Atg8-PE) from the unmodified form, followed by immunoblotting using antibodies against Atg8 (anti-Atg8-2) ([@bib33]).

Alkaline phosphatase assay {#s4-6}
--------------------------

Lysates were prepared from cells before or after starvation for 4 hr in SD-N medium. The ALP assay was carried out as described previously ([@bib38]; [@bib40]).
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Reviewing Editor
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China

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Two distinct mechanisms target the autophagy-related E3 complex to the pre-autophagosomal structure\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Ivan Dikic as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Upon autophagy induction in yeast, a set of Atg proteins is recruited in a hierarchical order to the PAS. The Atg1 complex acts in the most upstream of the recruitment. Previous studies have shown that the Atg12-Atg5-Atg16 complex, which acts as a E3 for promoting lipidation of Atg8, is targeted to PAS via interaction with Atg21 in a PI(3)P-dependent manner. In this manuscript, the authors revealed a novel mechanism for the PAS targeting of the Atg12-Atg5-Atg16 complex. They demonstrated that this complex can be recruited to the PAS via direct interaction of the N-terminal region of Atg12 with the Atg1 complex. The formation of Atg17 puncta is reduced in the absence of the Atg12-Atg5-Atg16 complex, suggesting a crosstalk between these two complexes. These findings provide novel and useful information for our understanding of the early stage of autophagy process. The experiments are well-designed, the data are with high quality, and the manuscript is well-written. It is suitable for publication in *eLife* after appropriate revisions.

Essential revisions:

1\) Which component(s) in the Atg1 complex interact with the N-terminal 56 amino acids of Atg12?

2\) Does the N-terminal part of Atg12 have the ability to localize by themselves to the PAS? The authors should try if proteins (such as GFP) can be directed to the PAS via this domain.

10.7554/eLife.43088.014

Author response

> Essential revisions:
>
> 1\) Which component(s) in the Atg1 complex interact with the N-terminal 56 amino acids of Atg12?

Thank you for asking this important question. In the revised manuscript, we first performed yeast two-hybrid assay to examine the interactions of all the Atg1 complex components with Atg12, and consequently, only Atg17 was suggested to directly interact with Atg12 (Figure 2---figure supplement 2A-C). We further confirmed this interaction by coimmunoprecipitation analysis in cells lacking the four components of the Atg1 complex other than Atg17 (Figure 2---figure supplement 2D). Thus, these new results suggest that Atg17 is the component of the Atg1 complex that interacts with Atg12.

> 2\) Does the N-terminal part of Atg12 have the ability to localize by themselves to the PAS? The authors should try if proteins (such as GFP) can be directed to the PAS via this domain.

Given that Atg5-GFP, which should exist as a conjugate with Atg12, cannot localize to the PAS in the absence of Atg16, the N-terminal region of Atg12 alone was thought not to localize to the PAS, either. However, as this was an interesting open question, we experimentally examined it and showed that Atg12^WT^-GFP, Atg12^N56^-GFP,and Atg12^N100^-GFPwere dispersed throughout the cytoplasm and unable to localize to the PAS as shown below ([Author response image 1](#respfig1){ref-type="fig"}).

![Cells were treated with rapamycin for 2 h, and examined by fluorescence microscopy.](elife-43088-resp-fig1){#respfig1}

We did not include these results in the revised manuscript.
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